Clinical trials: Spinocerebellar Ataxia Type 2
Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2
Priming Motor Learning Through Exercise in People With Spinocerebellar Ataxia
PRIME-Ataxia is a randomized controlled trial that aims to determine the feasibility and efficacy of an 8-week telehealth intervention of high intensity aerobic exercise prior to balance training compared to an 8-week telehealth…
- Conditions
- Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia Type 3, Spinocerebellar Ataxia Type 6
- Trial name
- PRIME-Ataxia (NCT05826171)
- Testing
- High-Intensity Aerobic Exercise Prior to Balance Training, Low-Intensity Exercise Prior to Balance Training
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Teachers College, Columbia University
Spinocerebellar Ataxia Type 3
STRIDES - a Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia
Phase 2b/3 double blind, randomized, placebo-controlled trial to assess safety and efficacy of SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion) for the treatment of adults with spinocerebellar ataxia).
- Trial name
- STRIDES (NCT05490563)
- Testing
- SLS-005
- Where
- 23 sites in United States, Australia and 6 more
- Volunteers
- 23 people
- Sponsor
- Seelos Therapeutics, Inc.
Spinocerebellar Ataxia Type 3
Identification of Biomarkers in Spinocerebellar Ataxia 3
The purpose of this study is to examine the differences in cerebral spinal fluid (CSF) and blood of patients with spinocerebellar ataxias and healthy volunteers.
- Trial name
- SCA3 (NCT03885167)
- Testing
- Specimen Collection
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Spinocerebellar Ataxia Type 3
A Pharmacokinetics and Safety Study of BIIB132 in Adults With Spinocerebellar Ataxia 3
The primary objective of this study is to evaluate the safety and tolerability of multiple ascending doses of BIIB132 administered via intrathecal (IT) injection to participants with spinocerebellar ataxia type 3 (SCA3).
- Trial name
- NCT05160558
- Testing
- BIIB132
- Where
- 20 sites in United States, Germany and 4 more
- Volunteers
- 8 people
- Sponsor
- Biogen
Spinocerebellar Ataxia Type 3
Efficacy Of Oral Trehalose In Spinocerebellar Ataxia 3
This study evaluates the effectiveness of oral trehalose in alleviating the neuropathological and motor behaviour deficits among patients with SCA3.
- Trial name
- NCT04399265
- Testing
- Trehalose, Maltose
- Where
- Malaysia
- Volunteers
- 20 people
- Sponsor
- National University of Malaysia
Spinocerebellar Ataxia Type 3
Repetitive Transcranial Magnetic Stimulation in SCA3 Patients
Machado-Joseph Disease (MJD) or spinocerebellar ataxia type 3 (SCA3) is the most common spinocerebellar ataxia worldwide.Repetitive transcranial magnetic stimulation (rTMS) is a form of brain stimulation therapy used to treat…
- Trial name
- NCT05502432
- Testing
- Active repetitive transcranial magnetic stimulation
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Ning Wang, MD., PhD.
Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia 3
Clinical Trial Readiness for SCA1 and SCA3
The investigators plan to fill the gap between the current state of clinical trial readiness and the optimal one for SCA1 and SCA3, which are fatal rare diseases with no treatments.
- Trial name
- READISCA (NCT03487367)
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- The Methodist Hospital Research Institute
Spinocerebellar Ataxia - All Sub-types, Friedreich's Ataxia
Preliminary Study of the Scale To Assess Ataxia and Neurologic Dysfunction (STAND)
The objectives of this study are: To validate the inter-rater and intra-rater reliability of a new scale for the assessment of ataxia and neurologic dysfunction (STAND) To assess common constructs and correlation between STAND…
- Trial name
- STAND (NCT02179333)
- Testing
- Ataxia rating scale
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of South Florida
Spinocerebellar Ataxia Type 10
Genetic Mechanism of Conserved Ancestral Haplotype in SCA10
Spinocerebellar ataxia type 10 (SCA10) is a hereditary ataxia whose ancestral mutation occurred in East Asia. The mutation is likely to have migrated during peopling of American continents from East Asia.
- Trial name
- CAHSCA10 (NCT04495426)
- Testing
- Non-interventional study
- Where
- 3 sites in United States, Brazil
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- The Methodist Hospital Research Institute
Spinocerebellar Ataxia Type 2
Clinical Trial With Riluzole in Spinocerebellar Ataxia Type 2 (ATRIL)
ATRIL is a multi-centric, double-blind randomized, two-arm controlled study. 42 SpinoCerebellar Ataxia type 2 (SCA2) patients, both gender, at least 18 years of age will be included.
- Trial name
- ATRIL (NCT03347344)
- Testing
- Riluzole
- Where
- France
- Volunteers
- 42 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Spinocerebellar Ataxias, Spinocerebellar Ataxia Type 1
Study of CAD-1883 for Spinocerebellar Ataxia
This is a randomized, double-blind, placebo-controlled Phase 2 study evaluating oral administration of CAD-1883 in the treatment of adults with a genotypic diagnosis of Spinocerebellar Ataxia (SCA).
- Conditions
- Spinocerebellar Ataxias, Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia Type 3
- Trial name
- Synchrony-1 (NCT04301284)
- Testing
- CAD-1883
- Where
- 6 sites in United States
- Sponsor
- Cadent Therapeutics
Ataxia, Spinocerebellar Ataxias
Cerebello-Spinal tDCS as Rehabilitative Intervention in Neurodegenerative Ataxia
Neurodegenerative cerebellar ataxias represent a group of disabling disorders which currently lack effective therapies. Cerebellar transcranial direct current stimulation (tDCS) is a non-invasive technique, which has been…
- Conditions
- Ataxia, Spinocerebellar Ataxias, Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2
- Trial name
- SCA02 (NCT04153110)
- Testing
- Anodal cerebellar and cathodal spinal tDCS
- Where
- Italy
- Volunteers
- 61 people
- Sponsor
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Spinocerebellar Ataxia Type 3, Machado-Joseph Disease
Neuropsychiatry and Cognition in SCA3/MJD
This research investigates how cognitive-affective aspects evolve during the course of SCA3/MJD. Due to COVID-19 pandemics, this study protocol was adapted for online-only consultations.
- Conditions
- Spinocerebellar Ataxia Type 3, Machado-Joseph Disease, SCA3, MJD
- Trial name
- NCT04714307
- Testing
- SCA3/MJD molecular diagnosis, Cognitive Testing, Psychiatric Evaluation
- Where
- Brazil
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Hospital de Clinicas de Porto Alegre
Spinocerebellar Ataxia Type 3, Machado-Joseph Disease
Natural History of Oculomotor Neurophysiology in Ataxic and Pre-ataxic Carriers of SCA3/MJD
The study will consist of a prospective observation of subjects in a natural history design. Disease progression will be monitored through clinical scales and video-oculography.
- Trial name
- BIGPRO (NCT04229823)
- Testing
- Video-oculography, Clinical Scales, Genotyping
- Where
- Brazil
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Hospital de Clinicas de Porto Alegre
Spinocerebellar Ataxia Type 3, Machado-Joseph Disease
Astrocytic Markers and the Pre-ataxic Period of SCA3/MJD - BIGPRO Study Astrocytes
The study will consist of a prospective observation of subjects in a natural history design. The investigators will monitor changes of clinical scales, quality of life, messenger ribonucleic acid (mRNA) of candidate genes (CCL11…
- Conditions
- Spinocerebellar Ataxia Type 3, Machado-Joseph Disease, SCA3, MJD
- Trial name
- NCT04419974
- Testing
- Molecular Diagnosis, Clinical Scales - Baseline, Blood Draw - Baseline
- Where
- Brazil
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Hospital de Clinicas de Porto Alegre
Ataxia, Cerebellar, Cerebellar Ataxia
Rehabilitative Trial With Cerebello-Spinal tDCS in Neurodegenerative Ataxia
Neurodegenerative cerebellar ataxias represent a group of disabling disorders for which we currently lack effective therapies. Cerebellar transcranial direct current stimulation (tDCS) is a non-invasive technique, which has been…
- Conditions
- Ataxia, Cerebellar, Cerebellar Ataxia, Spinocerebellar Ataxias, Ataxia, Spinocerebellar
- Trial name
- CStDCSAtaxia (NCT03120013)
- Testing
- Anodal cerebellar and cathodal spinal tDCS
- Where
- Italy
- Volunteers
- 21 people
- Sponsor
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Spinocerebellar Ataxia Type I
Lithium Treatment for Patients With Spinocerebellar Ataxia Type I
This study will evaluate the side effects and tolerability of the drug lithium in patients with spinocerebellar ataxia type I (SCA1) an inherited disorder caused by loss of nerve cells in parts of the brain.
- Trial name
- NCT00683943
- Testing
- Lithium Carbonate
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2
Biomarkers in Autosomal Dominant Cerebellar Ataxia
Autosomal dominant cerebellar ataxias (ADCA) are a group of neurodegenerative disorders that are clinically and genetically various.
- Conditions
- Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia, Autosomal Recessive 3, Episodic Ataxia, Type 7
- Trial name
- BIOSCA (NCT01470729)
- Testing
- metabolic and imaging biomarkers in SCA1,2,3 and 7 patients
- Where
- France
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Spinocerebellar Ataxia Type 6
Parkinsonism in Spinocerebellar Ataxia Type 6
The spinocerebellar ataxias (SCAs) are a genetically heterogeneous group of dominantly inherited progressive ataxia disorders. More than 30 different gene loci have been identified so far.
- Trial name
- NCT01934998
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Chicago
Spinocerebellar Ataxias Type 1, Spinocerebellar Ataxias Type 2
Dalfampridine and Gait in Spinocerebellar Ataxias
Investigators expect there will be improvement in walking speed and steadiness after taking Dalfampridine, thereby improving activities of daily living and enhancing social and occupational functions for patients with…
- Conditions
- Spinocerebellar Ataxias Type 1, Spinocerebellar Ataxias Type 2, Spinocerebellar Ataxias Type 3, Spinocerebellar Ataxias Type 6
- Trial name
- NCT01811706
- Testing
- Dalfampridine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Florida